*Daratumumab added action to Revlimid and Decadron in Myeloma we are told!
*New important pathway : The PLK1 disturbing spindle cell assemby...
*Blinatumomab, beneficial in refractory B cell precursor ALL....
*Potentiation of T cell tumor recognition (of neoplastic transformation)
by 1. Anti-CTLA4-----Ipilimumab
2. Anti-PD1----PEMBRO
3. CAR-T cell therapy
*Volarsetib in AML for older patient (research)
*Adding Everolimus to Taxol-Herceptin failed to increase disease free survival. But it did in Her-2 negative patient......in front line! a 7 months improvement was reported (20 Vs 13 months). BOLERO-3 is talking!
